<DOC>
	<DOCNO>NCT01676493</DOCNO>
	<brief_summary>This multicenter , open-label study evaluate safety PK oral codeine sulfate pediatric subject mild moderate post-procedural pain .</brief_summary>
	<brief_title>A Study Oral Codeine Sulfate Pediatric Patients With Post-procedural Pain</brief_title>
	<detailed_description>Eligible pediatric subject complete screening procedure within 14 day schedule procedure . Screening permitted day procedure . At screening , subject 's parent guardian provide write parental permission/informed consent participate study subject provide assent ( required local Institutional Review Board [ IRB ] ) protocol-specified procedure assessment perform . Subjects may inpatients , outpatient , day-surgery patient study site undergo procedure expect result least mild moderate post-procedure pain day procedure note Day 0 , follow discharge study site .</detailed_description>
	<mesh_term>Codeine</mesh_term>
	<criteria>1 . Has parent guardian provide write parental permission/informed consent , subject assent ( required local IRB ) . 2 . Is child 2 year old 17 year old , inclusive ( time inform consent signing ) . 3 . Has routine pediatric procedure expect cause least mild moderate pain . 4 . Is expect investigator require minimum one ( 1 ) dose oral codeine treatment mild moderate postprocedural pain . 5 . Has ability read understand study procedure ability communicate meaningfully study investigator staff ( subject preverbal age read communicate meaningfully , subject 's parent guardian must meet criterion ) . 6 . If female subject childbearing potential , must negative urine serum pregnancy test result day schedule procedure prior procedure . In population , female childbearing potential define onset menarche , , menstruation , whether irregular regular interval ( period ) . 7 . Must vascular access facilitate multiple blood draw . 1 . Is currently lactate . 2 . Has significant medical disease ( ) , laboratory abnormality , condition ( ) investigator 's judgment could compromise subject 's welfare , ability communicate study staff , complete study activity , would otherwise contraindicate study participation . 3 . Weighs le 10.5 kg . ( see Table 4 Maximum Number Doses Study Drug Weight detail ) 4 . Has weight ≤ 5th ≥ 95th percentile age base CDC Growth Charts . ( see Appendix 6 ) 5 . Has receive codeine , hydrocodone , morphine oxycodone form previous seven ( 7 ) day . 6 . Has use opioids chronically ( e.g. , codeine , morphine , oxycodone , hydrocodone , hydromorphone ) &gt; 7 calendar day within previous 30 day surgery . 7 . Has know hypersensitivity contraindication receive oral opioid ( ) . 8 . Has active enteral malabsorption disorder . 9 . Has impair liver function ( e.g. , alanine aminotransferase [ ALT ] ≥3 time upper limit normal [ ULN ] , bilirubin ≥3 time ULN ) , know active hepatic disease ( e.g. , hepatitis ) , evidence clinically significant chronic liver disease condition affect liver ( e.g. , chronic hepatitis ) may suggest potential increased susceptibility hepatic toxicity oral codeine exposure . NOTE : Subjects previous history liver function impairment may enrol result available screen laboratory sample . 10 . Has significantly impair renal function disease , evidence estimate glomerular filtration rate ( i.e. , creatinine level use Schwartz formula ) calculate less onethird ( 1/3 ) normal applicable age study population . NOTE : Subjects previous history kidney function impairment may enrol result available screen laboratory sample . 11 . Is undergoing procedure treatment acute burn . 12 . Has history substance abuse evidence current substance abuse , investigator 's opinion . 13 . Has participate interventional clinical study ( investigational market product ) within 30 day screen , plan participate another clinical trial next 30 day .</criteria>
	<gender>All</gender>
	<minimum_age>2 Years</minimum_age>
	<maximum_age>17 Years</maximum_age>
	<verification_date>February 2014</verification_date>
</DOC>